Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: J Pediatr Gastroenterol Nutr. 2019 Aug;69(2):e54. doi: 10.1097/MPG.0000000000002173

Esophagitis Dissecans Superficialis Diagnosed by Unsedated Transnasal Esophagoscopy

Racha T Khalaf *, Pooja Mehta *, Mark A Lovell , Joel A Friedlander *,
PMCID: PMC10234593  NIHMSID: NIHMS1888360  PMID: 30320667

graphic file with name nihms-1888360-f0001.jpg

A 20-year-old man with a complex psychiatric history on sertraline presented to the emergency department with 1 day of odynophagia, emesis, and sensation of esophageal impaction. Abnormal ingestion was denied. Review of systems and radiographic studies were negative. Unsedated transnasal esophagoscopy was performed. Mid and distal esophageal sloughing of vertical strips of the esophageal mucosa was noted (A–B). Hematoxylin and eosin staining findings were consistent with a diagnosis of esophagitis dissecans superficialis (EDS) (C). Fungal stain and culture and immunostains for herpes simplex virus and cytomegalovirus were negative. Patient was discharged on sucralfate and proton pump inhibitor for management of esophagitis and odynophagia.

EDS is a recently described, under-recognized, clinicopathologic diagnosis characterized by desquamation of the esophagus (1,2). An association between EDS and use of psychoactive mediations has been described (1). Cases of EDS typically self-resolve and have not been associated with long-term complications. When endoscopic and histopathologic data are consistent with a diagnosis of EDS, further workup and pharmacologic therapies can be minimized. Transnasal esophagoscopy in an acute care setting can be considered for evaluation and diagnosis of suspected esophageal disease.

Funding Sources:

Dr Khalaf is a recipient of a Cystic Fibrosis grant (grant number: Khalaf17B0).

Footnotes

Conflicts of interest:

Dr Friedlander is the president, chief medical officer, and co-founder of Triple Endoscopy, Inc. Dr Friedlander is listed as co-inventor on University of Colorado patents pending US 62/184,077, PCT/US2016/039352, AU201683112, CA 2,990,182,EU 16815420.1, JP 2017-566710, US 15/850,939, US 15/853,521, US15/887,438, and US 62/680,798 039352 related to endoscopic methods and technologies.

REFERENCES

  • 1.Hart PA, Romano RC, Moreira RK, et al. Esophagitis dissecans superficialis: clinical, endoscopic, and histologic features. Dig Dis Sci 2015;60:2049–57. [DOI] [PubMed] [Google Scholar]
  • 2.Carmack SW, Vemulapalli R, Spechler SJ, et al. Esophagitis dissecans superficialis (“sloughing esophagitis”): a clinicopathologic study of 12 cases. Am J Surg Pathol 2009;33:1789–94. [DOI] [PubMed] [Google Scholar]

RESOURCES